10x Genomics (10x Genomics) Net Issuance of Preferred Stock

: $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

10x Genomics's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. The number is 0, which means that 10x Genomics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

10x Genomics's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

10x Genomics Net Issuance of Preferred Stock Historical Data

The historical data trend for 10x Genomics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

10x Genomics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock																-	-	-	-	-

10x Genomics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

10x Genomics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics (10x Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Executives

Serge Saxonov	director, 10 percent owner, officer: Chief Executive Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur	officer: Chief Commercial Officer	C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson	director, officer: See Remarks	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear	officer: Chief Financial Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel	director	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen	director	THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield	officer: Chief Commercial Officer	6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts	director	C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc	10 percent owner	2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006